Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Prothena Corporation plc (NASDAQ:PRTA) today announced partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLE) from both PADOVA and the Phase II PASADENA study.
'As pioneers in developing the first anti-alpha-synuclein targeting antibody, we are excited to see Roche advancing prasinezumab into Phase III development, with the potential to deliver the first disease-modifying treatment option to the millions of individuals living with Parkinson's disease and their families,' stated Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.
Multiple endpoints from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson's disease. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, although missed statistical significance. Positive trends towards reduced motor progression at 104 weeks (two years) were observed; these effects appear to be sustained over longer treatment periods based on additional OLE data. The PADOVA study also provided the first biomarker evidence of prasinezumab impacting the underlying disease biology.
The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson's disease, are ongoing.
About Prasinezumab
Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease.
Data from the Phase IIb PADOVA study suggest the possible clinical benefit of prasinezumab on top of effective symptomatic treatment in early-stage Parkinson's disease. PADOVA investigated prasinezumab in 586 people with early-stage Parkinson's disease, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01], although the study missed statistical significance (p=0.0657). In a pre-specified analysis, the effect of prasinezumab was more pronounced in the population treated with levodopa (75% of participants), HR=0.79 [0.63-0.99], p=0.0431 (nominal). Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Trends towards reduced motor progression at 104 weeks (two years) were observed, showing 30-40% relative reduction versus placebo across the overall and levodopa-treated populations.
Prasinezumab continues to be well tolerated and no new safety signals were observed in the study. The safety database for prasinezumab consists of data from more than 900 Parkinson's disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years.
In December 2013, Prothena and Roche entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab. Roche has sole responsibility for developing and commercializing prasinezumab and has agreed to pay Prothena up to double-digit teen royalties on net sales. To date, Prothena has earned $135 million with up to $620 million in additional milestone payments that include regulatory and sales milestones. In addition, Prothena has an option to co-promote prasinezumab in the U.S.
About Parkinson's disease
Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disease characterized by the gradual loss of neurons that make dopamine and other nerve cells. Today, Parkinson's disease affects over 10 million people worldwide. The prevalence of Parkinson's disease is increasing, and it has become one of the fastest-growing neurological disorders. Currently, symptomatic treatments that effectively alleviate motor symptoms are available. However, no therapies slow down or stop the clinical progression of Parkinson's disease.
About Prothena
Prothena Corporation plc is a clinical-stage biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Parkinson's disease and a number of other neurodegenerative diseases. For more information, please visit the Company's website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, design, and proposed mechanism of action prasinezumab; plans for ongoing and future clinical trials of prasinezumab; and amounts we might receive under our collaboration with Roche. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the 'Risk Factors' sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250615297680/en/
CONTACT: Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308,[email protected]
Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974,[email protected]
KEYWORD: EUROPE IRELAND UNITED KINGDOM
INDUSTRY KEYWORD: HEALTH NEUROLOGY CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Prothena Corporation plc
Copyright Business Wire 2025.
PUB: 06/16/2025 01:06 AM/DISC: 06/16/2025 01:05 AM
http://www.businesswire.com/news/home/20250615297680/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Electric vehicle sales growth eases to 21% in July, research firm says
By Alessandro Parodi (Reuters) -Global electric vehicle sales grew 21% year-on-year in July, the slowest rate since January and down from 25% in June, as momentum in plug-in hybrid sales in China slackened, market research firm Rho Motion said on Wednesday. WHY IT'S IMPORTANT China is the world's biggest car market and accounts for more than half of global EV sales, which in Rho Motion's data include battery-electric vehicles and plug-in hybrids. Its overall car sales growth slowed in July, with BYD, the world's largest EV maker, recording its third monthly drop in registrations. The relatively muted slowdown in overall EV sales however shows other markets are taking up some of the slack, with European sales for one benefiting from incentives aimed at speeding up decarbonisation. BY THE NUMBERS Global sales of battery-electric vehicles and plug-in hybrids rose to 1.6 million units in July, Rho Motion data showed. China's EV sales growth, which averaged 36% a month in the first half, eased to 12% in July as the previously booming market was dampened by a pause in some 2025 government subsidy schemes for EV and plug-in hybrid purchases, Rho Motion data manager Charles Lester said. Chinese sales reached around one million vehicles. European sales surged 48% to about 390,000 units, while North American sales climbed 10% to more than 170,000. Sales in the rest of the world jumped 55% to more than 140,000 vehicles. KEY QUOTE "Despite regional variations, the overall trajectory for EV adoption in 2025 remains strongly upward," Lester said. WHAT'S NEXT Chinese car sales are expected to return to strong growth from August as new funds become available for its subsidy schemes, while a cut in U.S. tax credits for buying or leasing new EVs at the end of September will hurt demand there, Lester added. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
CPR questions to be added to driving theory test
Learner drivers are to be quizzed on their CPR skills in an update to the theory test. The Driver and Vehicle Standards Agency (DVSA) – which oversees driving tests in Britain – said motorists are often 'first on the scene' when someone suffers a cardiac arrest. Adding questions on CPR and defibrillators to the theory test from early next year means candidates will 'have a better understanding of the skills to use in an emergency', it added. More than 40,000 people in the UK suffer an out-of-hospital cardiac arrest each year, with fewer than one in 10 surviving. Research has found survival rates can be as high as 70% if CPR is given and a defibrillator used within three to five minutes of collapse. DVSA chief driving examiner Mark Winn said: 'Part of being a safe and responsible driver is knowing what to do in an emergency – how to step in and make a real, life-saving difference. 'Learning CPR and how to use a defibrillator is a very simple skill, and adding this into the official learning resource is a great way for DVSA to support the drive to raise awareness.' The push for the change was led by Professor Len Nokes – chair of the Save a Life Cymru scheme – whose 24-year-old daughter Claire died in 2017 from complications following a cardiac arrest. He said: 'When Claire, my daughter, had her cardiac arrest, some knowledge of CPR might have made a difference. 'I don't want any other family to go through this experience. 'All of us in this partnership hope that by making CPR and how to use a defibrillator part of the theory test, we will be able to significantly increase the number of people who have this life-saving awareness.' James Cant, chief executive of charity Resuscitation Council UK, said: 'By embedding these life-saving skills into such a widely-taken assessment, we can help ensure that more people, from all communities, gain the knowledge and confidence to act during a cardiac arrest.' Learners must pass the theory driving test before booking a practical test. Theory test candidates are required to get at least 43 out of 50 multiple-choice questions correct, covering areas such as road signs, traffic laws, vehicle safety and first aid. They must also pass a hazard perception video test. More than two million theory tests are taken each year, with a pass rate of about 45%.
Yahoo
an hour ago
- Yahoo
New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management
Groundbreaking research by Professor Richard Costello leads to innovative digital health platform DUBLIN, August 12, 2025--(BUSINESS WIRE)--Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies published in Lancet Respiratory Medicine and validated by health economists, Phyxiom's platform provides clinicians with precise, real-time data to significantly enhance asthma and Chronic Obstructive Pulmonary Disease (COPD) management. Co-founded by experienced tech executive Grace O'Donnell as Chief Executive Officer and healthcare professional Elaine Mac Hale as Clinical Operations Director, along with Prof Costello, Phyxiom is a spin-out company from RCSI. Based on a strong foundational IP portfolio developed under an Enterprise Ireland (EI) Commercialisation Fund award the company has recently achieved EI High Potential Start- Up (HPSU) status. O'Donnell and Mac Hale lead Phyxiom's day-to-day operations, driving forward its mission to revolutionise respiratory healthcare through advanced digital solutions. Professor Richard Costello, Chief Medical Officer at Phyxiom and Professor of Respiratory Medicine at RCSI, explained the science behind the innovation: "Our research, spanning over a decade, has conclusively demonstrated that digitally-informed treatment significantly reduces medication use, prevents unnecessary hospitalisations, and ultimately lowers healthcare costs. By providing clinicians with objective, real-time insights into lung function and medication adherence, Phyxiom fundamentally improves diagnosis accuracy and treatment outcomes." Phyxiom's technology is already operational across 13 Health Service Executive (HSE) asthma clinics in Ireland, processing nearly 350 patients to date, with plans to expand further and engage Irish private health insurers in 2025. Grace O'Donnell, CEO, said: "Elaine and I are incredibly proud to lead this exciting RCSI spin-out company into the commercial market. We are passionate about using Richard's groundbreaking research as the foundation to deliver transformative, patient-centric healthcare solutions, significantly improving quality of life for patients suffering from uncontrolled asthma and COPD." Elaine Mac Hale, Clinical Operations Director, added: "Phyxiom seamlessly integrates into existing healthcare systems, ensuring minimal disruption to clinicians' workflows. Our evidence-based approach empowers healthcare providers with the insights needed to deliver personalised, effective, and efficient patient care." Following its successful Irish rollout, Phyxiom is expanding into the UK market in H1 2026 and plans a US launch in 2027, supported by established partnerships and integration with leading electronic health record systems. Phyxiom's launch marks a significant milestone in Ireland's healthtech landscape, highlighting Irish innovation on the global healthcare stage. Those interested in learning more about Phyxiom, can visit the website here: About RCSI University of Medicine and Health Sciences RCSI University of Medicine and Health Sciences is ranked first in the world for its contribution to UN Sustainable Development Goal 3, Good Health and Well-being, in the Times Higher Education (THE) University Impact Rankings 2025. Founded in 1784 as the Royal College of Surgeons in Ireland with responsibility for training surgeons in Ireland, today RCSI is an innovative, not-for-profit, international university exclusively focused on driving improvements in human health worldwide through education, research and engagement. RCSI is among the top 300 universities worldwide in the World University Rankings (2025) and has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education. In 2026, RCSI will open a new public engagement space, dedicated to health and well-being, at 118 St Stephen's Green in Dublin city centre. The space is designed to engage the public in dialogue about living longer, healthier and happier lives through dynamic events and exhibitions. Our aim is to bridge the gap between health sciences research, professional expertise, and public understanding, empowering people to make informed decisions about their health. Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise. View source version on Contacts phyxiom@ or call Lewis Oakley or Kirsty Leighton on +44 20 3637 7310 Sign in to access your portfolio
